Provided are uses of shortened fibers of poly-N-acetylglucosamine comprising N-acetylglucosamine monosaccharides and/or glucosamine monosaccharides (“sNAG nanofibers”), wherein more than 50% of the sNAG nanofibers are between about 1 to 15 µm in length or the average length of the sNAG nanofibers is between 4 to 7 µm, and wherein more than 70% of the monosaccharides are N-acetylglucosamine monosaccharides for the treatment of cosmetic and therapeutic conditions of the skin and connective tissues. The nanofibers can be used for the treatment of wrinkles and as dermal fillers. The nanofibers can be used for regenerating tissue, reducing scarring, reducing fibrosis or reducing adhesions associated with a wound and for treating Ehlers-Danlos syndrome, scleroderma, Epidermolysis bullosa, osteoporosis, intravertebral disc disorder, degenerative disc disorder or osteoarthritis.
